McKesson Corporation


SKU: MCK Category:


McKesson managed to exceed the revenue expectations as well as the earnings expectations of Wall Street. In the second quarter, they reported a 10% increase in revenues to $77.2 billion, with adjusted earnings per diluted share reaching $6.23. The Distribution business showcased robust growth in the US Pharmaceutical segment, consistently achieving double-digit revenue increases over the past ten quarters. The second quarter saw significant revenue growth attributed to strong prescription volume trends, particularly in GLP-1 medications. In the Medical-Surgical segment, McKesson adapted to evolving market dynamics, noting general moderations in primary care foot traffic and a decline in respiratory illness and flu instances. Despite these challenges, confidence in the business fundamentals and the strength of scaled assets within the Medical-Surgical segment remained steadfast. Addressing the expansion of oncology and biopharma platforms, the company highlighted the addition of four new practices and hundreds of providers to the US Oncology network. The integration involved leveraging resources like the iKnowMed electronic health record system, contributing to its recognition as a top-ranked medical oncology EHR in the 2023 Best-in-Class report. The biopharma services platform achieved double-digit growth in revenue and adjusted operating profit.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!